Last reviewed · How we verify
Insulin lispro mix 25
Insulin lispro mix 25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.
Insulin lispro mix 25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin lispro mix 25 |
|---|---|
| Also known as | Humalog Mix25, insulin lispro biphasic |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin analog, premixed formulation |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This is a premixed insulin formulation containing 25% insulin lispro (rapid-acting) and 75% insulin lispro protamine suspension (intermediate-acting). Insulin lispro is a recombinant human insulin analog with a faster onset and shorter duration than regular human insulin. The mixture allows for both immediate postprandial glucose control and basal coverage, mimicking physiologic insulin secretion patterns.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Glucagon Counterregulation in Type 1 Diabetes (NA)
- Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients (PHASE3)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects (NA)
- A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy (PHASE4)
- Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 (PHASE1, PHASE2)
- BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance (PHASE1, PHASE2)
- Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus (PHASE1)
- Comparison of Insulin Mix25 Versus Mix50 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |